This book explores a range of infections in hematology. It draws on extensive clinical experience and the results of modern research, and identifies new directions in this area of clinical medicine. It is known that, along with progress in medicine, the evolution of microbes also occurs, with resistance to antibiotics growing and new forms of infectious diseases emerging. As such, the findings of this book are particularly timely.
He is a principal investigator in various clinical trials and observational studies in the area of infectious diseases and hematology, with more than 50 published research papers to his credit. He has served as a research advisor in various clinical studies, with more than published research papers to his credit.
Health Sciences. Life Sciences. Physical Sciences. Social Sciences. Expert Opin Drug Saf. A review of CDtargeted immunotherapies for relapsed or refractory acute lymphoblastic leukemia. J Oncol Pharm Pract. Clin Cancer Res. Adcetris summary of product characteristics. Accessed 22 November CD30 in normal and neoplastic cells. Clin Immunol. Eur J Immunol. Muta H, Podack ER. CD from basic research to cancer therapy.
Passar bra ihop
Immunol Res. J Clin Oncol. Brentuximab vedotin SGN in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. Case Rep Pulmonol. Cancer Sci. J Chemother. Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Open Forum Infect Dis. US Food and Drug Administration. Accessed 6 August Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions SONAR project.
Changes in the natural history of progressive multifocal leukoencephalopathy in HIV-negative lymphoproliferative disorders: impact of novel therapies. Am J Hematol. Incidence of progressive multifocal leukoencephalopathy in patients without HIV. ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother. Calabrese L. A rational approach to PML for the clinician. Cleve Clin J Med. Local tumor treatment in combination with systemic ipilimumab immunotherapy prolongs overall survival in patients with advanced malignant melanoma.
Cancer Immunol Res. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. Improved survival with ipilimumab in patients with metastatic melanoma. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma KEYNOTE : a randomised, controlled, phase 2 trial. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer.
Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. Nivolumab versus everolimus in advanced renal-cell carcinoma. Tyrosine kinase inhibitors and immune checkpoint blockade in allogeneic hematopoietic cell transplantation. Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma. Blood Adv. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma.
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. PD-1 and its ligands in tolerance and immunity. Ann Rev Immunol. Role of PD-1 in regulating T-cell immunity. Curr Top Microbiol Immunol. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Checkpoint blockade in cancer immunotherapy. Adv Immunol.
Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Cell Mol Immunol. Immune-related adverse events with immune checkpoint blockade: a comprehensive review.
Eur J Cancer. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. Neutropenia in a patient treated with ipilimumab anti-CTLA-4 antibody. J Immunother. Severe agranulocytosis in a patient with metastatic non-small-cell lung cancer treated with nivolumab.
Lung Cancer. ESCMID Study Group for Infections in Compromised Hosts ESGICH consensus document on the safety of targeted and biological therapies: an infectious diseases perspective-immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine 1-phosphate receptor modulators and proteasome inhibitors. Clin Microbiol Infect. Management of immune-related adverse events and kinetics of response with ipilimumab. The spectrum of serious infections among patients receiving immune checkpoint blockade for the treatment of melanoma. Clin Infect Dis. Anti-PD1 antibody treatment and the development of acute pulmonary tuberculosis.
J Thorac Oncol. Blockade of endogenous B7-H1 suppresses antibacterial protection after primary Listeria monocytogenes infection. PDL-1 blockade impedes T cell expansion and protective immunity primed by attenuated Listeria monocytogenes. J Immunol. Management of toxicities of immune checkpoint inhibitors.
Infections in Hematology | Georg Maschmeyer | Springer
Cancer Treat Rev. Prevention and treatment of cancer-related infections. J Natl Compr Canc Netw. Ann Oncol. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat Commun. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia.
Ibrutinib versus ofatumumab in previously t reated chronic lymphoid leukemia. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma HELIOS : a randomised, double-blind, phase 3 study. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy.
Immunol Rev. Bruton OC. Front Immunol. Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib. Disseminated cryptococcosis with brain involvement in patients with chronic lymphoid malignancies on ibrutinib. Disseminated cryptococcal disease in a patient with chronic lymphocytic leukemia on ibrutinib. Case Rep Infect Dis. Cryptococcal infections in two patients receiving ibrutinib therapy for chronic lymphocytic leukemia.
Cryptococcal meningoencephalitis in patients with mantle cell lymphoma on ibrutinib. Lower extremity ecchymotic nodules in a patient being treated with ibrutinib for chronic lymphocytic leukemia. Miliary tuberculosis after initiation of ibrutinib in chronic lymphocytic leukemia. Progressive multi-focal leucoencephalopathy among ibrutinib-treated persons with chronic lymphocytic leukaemia.
Br J Haematol. Ibrutinib use complicated by progressive multifocal leukoencephalopathy. Progressive multifocal leukoencephalopathy after ibrutinib therapy for chronic lymphocytic leukemia. Cancer Res Treat. Leuk Res Rep. Risk of hepatitis B virus reactivation in patients treated with ibrutinib. Severe hepatitis B virus reactivation related to ibrutinib monotherapy. Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib. Ibrutinib-associated Pneumocystis jirovecii pneumonia.
Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib. Serious infections in patients receiving ibrutinib for treatment of lymphoid malignancies. Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma.
Cancer Cell. Grommes C, Younes A. Call for action: invasive fungal infections associated with ibrutinib and other small molecule kinase inhibitors targeting immune signaling pathways. Ibrutinib dosing strategies based on interaction potential of CYP3A4 perpetrators using physiologically based pharmacokinetic modeling. Clin Pharmacol Ther.
Randhawa JK, Ferrajoli A. A review of supportive care and recommended preventive approaches for patients with chronic lymphocytic leukemia. Expert Rev Hematol. Lack of adequate pneumococcal vaccination response in chronic lymphocytic leukaemia patients receiving ibrutinib. Ibrutinib may impair serological responses to influenza vaccination. Ibrutinib-induced pneumonitis in patients with chronic lymphocytic leukemia. PI3K signalling: the path to discovery and understanding.
Nat Rev Mol Cell Biol. The emerging mechanisms of isoform-specific PI3K signalling.
- World Programme of Action for Youth to the Year 2000 and beyond.
- Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units?
- Pilots flight operating instructions for army models P-39Q-1 airplane.
- Modern Challenges and Perspectives.
- Syntactic Pattern Recognition, Applications.
Phosphoinositide 3-kinase p delta regulates natural antibody production, marginal zone and B-1 B cell function, and autoantibody responses. Key role of the pdelta isoform of PI3K in B-cell antigen and IL-4 receptor signaling: comparative analysis of genetic and pharmacologic interference with pdelta function in B cells. CAL, a pdelta selective phosphatidylinositolkinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability.
The phosphoinositide 3'-kinase delta inhibitor, CAL, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Idelalisib impairs TREM-1 mediated neutrophil inflammatory responses. Sci Rep. Idelalisib, a selective inhibitor of phosphatidylinositol 3kinase-d, as therapy for previously treated indolent non-Hodgkin lymphoma.
PI3Kd inhibition by idelalisib in patients with relapsed indolent lymphoma. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukemia: an open-label, randomised phase 3 trial. Lancet Haematol. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial.
Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL. Safety and tolerability of idelalisib, lenalidomide and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A and A phase 1 trials.
A retrospective analysis of Pneumocystis jirovecii pneumonia infection in patients receiving idelalisib in clinical trials. Suppl 2. Zydelig Prescribing Information. Accessed 5 August Idelalisib in the management of lymphoma. Histone deacetylase inhibitors in cancer therapy. Histone deacetylase inhibitors impair innate immune responses to Toll-like receptor agonists and to infection.
HDAC inhibitors block innate immunity. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. Biomark Res. Romidepsin for the treatment of peripheral T-cell lymphoma.
Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide romidepsin in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes. Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment. Reddy SA. Crit Rev Oncol Hematol. A phase I study of pulse high-dose vorinostat V plus rituximab R , ifosphamide, carboplatin, and etoposide ICE in patients with relapsed lymphoma.
Am J Haematol. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
J Virol. Histone deacetylase inhibitors impair the elimination of HIV-infected cells by cytotoxic T-lymphocytes. PLoS Pathog. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov. Molecular pathways: increased susceptibility to infection is a complication of mTOR inhibitor use in cancer therapy. Xu J, Tian D. Hematologic toxicities associated with mTOR inhibitors temsirolimus and everolimus in cancer patients: a systematic review and meta-analysis.
Curr Med Res Opin. Risk of infections in renal cell carcinoma RCC and non-RCC patients treated with mammalian target of rapamycin inhibitors. Br J Cancer. Pneumocystis jirovecii pneumonia in renal transplant recipients occurring after discontinuation of prophylaxis: a case-control study. BMC Nephrol. Outcomes associated with mammalian target of rapamycin mTOR inhibitors in heart transplant recipients: a meta-analysis. Int J Cardiol.
Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma. Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibitors for malignancy. A meta-analysis of published trials. Acta Oncol. Tefferi A. Ruxolitinib targets DCs: for better or worse? The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo.
JAK inhibition induces silencing of T Helper cytokine secretion and a profound reduction in T regulatory cells. Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinib. Cancer Res. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.
Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.
J Hematol Oncol. JAK Inhibition with ruxolitinib versus best available therapy for myelofibrosis.
Safety and efficacy of ruxolitinib in an open label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of patients in the JUMP trial. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly RESPONSE-2 : a randomised, open-label, phase 3b study. Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of patients.
Safety and efficacy of ruxolitinib in myelofibrosis patients without splenomegaly. Progressive multifocal leukoencephalopathy associated with ruxolitinib. Bilateral toxoplasmosis retinitis associated with ruxolitinib. Cytomegalovirus retinitis in a patient who received ruxolitinib. An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor. Pulmonary cryptococcosis in a ruxolitinib-treated patient with primary myelofibrosis. Respir Med Case Rep. Cryptococcal meningoencephalitis associated with the long-term use of ruxolitinib.
Disseminated infections with Talaromyces marneffei in non-AIDS patients given monoclonal antibodies against CD20 and kinase inhibitors. Emerg Infect Dis. Pneumocystis jiroveci pneumonitis complicating ruxolitinib therapy. BMJ Case Rep. Published online Jun 2. Pneumocystis jirovecii pneumonia associated with ruxolitinib therapy in a patient with myelofibrosis.
Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units
Oncol Res Treat. Case-report: EBV driven lymphoproliferative disorder associated with ruxolitinib. BMC Hematol. Epstein-Barr virus gastric ulcer associated with ruxolitinib. Varicella-zoster virus meningoencephalitis in a patient treated with ruxolitinib. Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis.
Hepatitis B virus reactivation associated with ruxolitinib. Intern Med. Occult hepatitis B infection reactivation after ruxolitinib therapy. Dig Liver Dis. Management of viral hepatitis in patients undergoing haematopoietic stem cell transplantation: recommendations of the 5th European Conference on Infections in Leukemia ECIL Lancet Infect Dis. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. European Association for the Study of the Liver. European Association for the Study of the Liver clinical practice guidelines: management of chronic hepatitis B virus infection.
J Hepatol. Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis? Ruxolitinib associated tuberculosis presenting as a neck lump. Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: a case report. BMC Res Notes. Disseminated tuberculosis associated with ruxolitinib. Ruxolitinib-associated tuberculosis: a case of successful ruxolitinib rechallenge. Fatal tuberculosis during treatment with ruxolitinib. Ned Tijdschr Geneeskd. Pulmonary tuberculosis reactivation following ruxolitinib treatment in a patient with primary myelofibrosis.
Use of rifampin for treatment of disseminated tuberculosis in a patient with primary myelofibrosis on ruxolitinib. Reactivation of pulmonary tuberculosis following treatment of myelofibrosis with ruxolitinib. Case Rep Hematol. A myelofibrosis case that develops mycobacterial infection after ruxolitinib treatment. Int J Clin Exp Med. Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on patients. Hematol Oncol.
Ruxolitinib-associated infections: a systematic review and meta-analysis. Tefferi A, Pardanani A. Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. Mayo Clin Proc. Ruxolitinib treatment for GvHD in patients with myelofibrosis. Bone Marrow Transplant. Zhu H, Almasan A. Development of venetoclax for therapy of lymphoid malignancies. Drug Des Devel Ther. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.
Impact of venetoclax esposure on clinical efficacy and safety in patients with relapsed or refractory chronic lymphocytic leukemia. Clin Pharmacokinet. Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy. Sci Transl Med. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. Safety and pharmacodynamics of venetoclax ABT in a randomized single and multiple ascending dose study in women with systemic lupus erythematosus.
Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. Venclexta Prescribing Information. Management of venetoclax - posaconazole interaction in acute myeloid leukemia patients: evaluation of dose adjustments. Clin Ther. Download references.